Clairity raised $43 million to expand its AI mammography tool for predicting five-year breast cancer risk.
Key Details
- 1Clairity, founded in 2020 by Dr. Constance Lehman of Mass General, focuses on AI for breast cancer risk assessment.
- 2The company secured $43 million in Series B funding led by Ace Global Equity and Santé Ventures, with support from the Breast Cancer Research Foundation.
- 3Clairity Breast is the first AI tool to predict five-year breast cancer risk from standard mammograms.
- 4The product received FDA de novo authorization in May 2024.
- 5New funds will support commercialization and partnership expansion.
Why It Matters
Clairity's advancements could lead to earlier detection and prevention strategies using existing mammography infrastructure, potentially improving patient outcomes. The funding and FDA approval mark important milestones for AI adoption in radiology.
Source
Radiology Business
Related News
•AuntMinnie
AI Advances Push Opportunistic Imaging Into Clinical Focus
AI-powered opportunistic screening is transforming routine radiological images into proactive tools for risk detection of major diseases.
•AuntMinnie
AI Workflow Boosts Breast Cancer Detection and Equity
Deployment of an AI-driven breast cancer screening workflow improved detection rates while maintaining equity across racial and breast density subgroups.
•Radiology Business
RadNet Study: AI Boosts Breast Cancer Detection in Largest-Ever Real-World Analysis
A massive real-world study by RadNet shows AI-assisted mammography increased breast cancer detection by 21.6%.